QTRX vs. EYPT, PACB, LAB, CTKB, NAUT, DH, LYEL, AUNA, MLYS, and PHAR
Should you be buying Quanterix stock or one of its competitors? The main competitors of Quanterix include EyePoint Pharmaceuticals (EYPT), Pacific Biosciences of California (PACB), Standard BioTools (LAB), Cytek Biosciences (CTKB), Nautilus Biotechnology (NAUT), Definitive Healthcare (DH), Lyell Immunopharma (LYEL), Auna (AUNA), Mineralys Therapeutics (MLYS), and Pharming Group (PHAR). These companies are all part of the "medical" sector.
EyePoint Pharmaceuticals (NASDAQ:EYPT) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
Quanterix has a net margin of -28.82% compared to Quanterix's net margin of -157.77%. EyePoint Pharmaceuticals' return on equity of -10.39% beat Quanterix's return on equity.
EyePoint Pharmaceuticals presently has a consensus price target of $33.71, indicating a potential upside of 184.75%. Quanterix has a consensus price target of $30.60, indicating a potential upside of 76.47%. Given Quanterix's higher possible upside, equities analysts plainly believe EyePoint Pharmaceuticals is more favorable than Quanterix.
99.4% of EyePoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 13.1% of EyePoint Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
EyePoint Pharmaceuticals has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.
In the previous week, EyePoint Pharmaceuticals had 19 more articles in the media than Quanterix. MarketBeat recorded 27 mentions for EyePoint Pharmaceuticals and 8 mentions for Quanterix. EyePoint Pharmaceuticals' average media sentiment score of 1.07 beat Quanterix's score of 0.30 indicating that Quanterix is being referred to more favorably in the news media.
Quanterix has higher revenue and earnings than EyePoint Pharmaceuticals. Quanterix is trading at a lower price-to-earnings ratio than EyePoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
EyePoint Pharmaceuticals received 184 more outperform votes than Quanterix when rated by MarketBeat users. Likewise, 69.81% of users gave EyePoint Pharmaceuticals an outperform vote while only 61.66% of users gave Quanterix an outperform vote.
Summary
EyePoint Pharmaceuticals beats Quanterix on 10 of the 19 factors compared between the two stocks.
Get Quanterix News Delivered to You Automatically
Sign up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quanterix Competitors List
Related Companies and Tools
